e-learning
resources
European Respiratory Review
2013
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future},
Katerina M. Antoniou, George A. Margaritopoulos, Nikos M. Siafakas
Source:
Eur Respir Rev 2013; 22: 281-291
Journal Issue:
September 2013 - 22 (129)
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Katerina M. Antoniou, George A. Margaritopoulos, Nikos M. Siafakas. Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future},. Eur Respir Rev 2013; 22: 281-291
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Chronic post-embolic pulmonary hypertension: a new target for medical therapies?},
Source: Eur Respir Rev 2013; 22: 258-264
Year: 2013
Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis?
Source: Eur Respir J 2003 Dec 01;22(6):906-911
Year: 2003
The therapy of idiopathic pulmonary fibrosis: what is next?
Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019
Year: 2019
Staging of idiopathic pulmonary fibrosis: past, present and future
Source: Eur Respir Rev 2014; 23:220-224
Year: 2014
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017
Year: 2017
PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery
Source: Eur Respir Rev 2013; 22: 148-152
Year: 2013
Common pathways in idiopathic pulmonary fibrosis and cancer},
Source: Eur Respir Rev 2013; 22: 265-272
Year: 2013
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
Targeted treatment of idiopathic pulmonary fibrosis: one step at a time
Source: Eur Respir J 2016; 47:1321-1323
Year: 2016
Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard
Source: Eur Respir J 2015; 45: 1208-1210
Year: 2015
Treatment of pulmonary exacerbations in cystic fibrosis},
Source: Eur Respir Rev 2013; 22: 205-216
Year: 2013
The role of infection in the pathogenesis of idiopathic pulmonary fibrosis},
Source: Eur Respir Rev 2013; 22: 376-381
Year: 2013
Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?
Source: Eur Respir Rev 2011; 20: 201-207
Year: 2011
Idiopathic pulmonary fibrosis: present understanding and future options
Source: Eur Respir Rev 2011; 20: 132-133
Year: 2011
Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation
Source: Eur Respir J 2012; 40: 794-795
Year: 2012
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials
Source: Eur Respir J 2015; 46: 243-249
Year: 2015
Emerging anti-inflammatory strategies for COPD},
Source: Eur Respir J 2012; 40: 724-741
Year: 2012
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept